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Mucosal melanomas are rare, accounting for only 1.4% of all melanomas. Only 18% of mucosal 
melanomas are vulvovaginal in origin, making it exceedingly rare. Mucosal melanomas typically 
carry a worse prognosis than those arising from cutaneous sites with a higher risk of recurrence 
and disseminated disease. We report a rare case of vaginal melanoma presenting as 
postmenopausal bleeding and discuss management of this disease. 
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Introduction 
In addition to arising from the skin, melanomas may arise from the mucosal lining of the 
respiratory, gastrointestinal, and genitourinary tracts, all of which contain melanocytes. Mucosal 
melanomas make up only about 1.4% of all melanomas in the United States.1 They are more 
common in women compared to men (2.8 per million vs. 1.5 per million) and in whites 
compared to blacks (2:1) when talking about absolute numbers of patients, but the racial 
difference is not as marked as with cutaneous melanoma (16:1).2 Mucosal melanomas account 
for 4.7% of melanomas occurring in black men compared to less than 1% of those occurring in 
white men. Likewise, mucosal melanomas make up 13.4% of melanomas in black women 
compared to 2.1% in white women.1 A study of ethnic Chinese seen at one institution in China 
noted 23% of their 522 cases of melanoma seen since 2006 were mucosal.3 Authors hypothesize 
that native Chinese may differ in risk to those who immigrated to the United States.  
The most common sites of mucosal melanoma are the sinuses, oral cavity, vulvovaginal, and 
anorectal regions.2 Only 18% of mucosal melanomas are vulvovaginal in origin with 77% of 
these being vulvar and 20% being vaginal, making vaginal melanoma exceedingly rare. The 
etiology of mucosal melanomas is unclear, but it differs from cutaneous melanoma in that it is 
not UV light-induced. Evidence is lacking linking it to human papillomavirus, human herpes 
virus, or polyomavirus.2 Mucosal melanomas typically carry a worse prognosis than those arising 
from cutaneous sites with a higher risk of recurrence and disseminated disease.2  
We report a rare case of vaginal melanoma causing postmenopausal bleeding and discuss the 




An 80-year-old female presented to her gynecologist for vaginal bleeding. A pap smear was 
negative for cervical cancer. Saline infusion sonohysterography revealed a 6 mm endometrial 
stripe and an irregular polyploid lesion in the uterine cavity removed by dilation and curettage. 
The pathology of this lesion was benign. The patient reported no vaginal bleeding for two 
months but then it returned, much heavier than before. At this time exam revealed four lesions 
which were biopsied: two vulvar, one vaginal, and one periurethral. The pathology of the left 
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vulvar lesion showed hyperpigmentation and a melanocytic macule. The pathology of the right 
vulvar lesion showed reactive changes. A shave biopsy of the polyploid lesion on the right side 
of the vaginal introitus revealed malignant melanoma. A brush biopsy of the periurethral lesion 
also revealed malignant melanoma. A PET/CT scan showed hypermetabolic left groin nodes and 
increased uptake near the lesion at the vaginal introitus. The patient underwent wide local 
excision of the vagina and vulva and left inguinal node dissection. Two of the ten groin nodes 
were positive for melanoma. She was NRAS and c-KIT wild type (absent mutation). The 
periurethral lesion was a local metastasis. She received external beam and high dose vaginal 
brachytherapy and adjuvant chemotherapy with 5 cycles of cisplatin (6th cycle held due to 
increased creatinine) and 6 cycles of temozolomide completing treatment by March of 2014. 





Figure 1. Mucosal melanoma involving vaginal epithelium stained with S100 for melanoma 













We report a case of vaginal melanoma presenting as post-menopausal bleeding. Vaginal 
melanoma is rare with about 500 cases reported in the literature.4 The majority of vaginal 
melanoma cases occur in women with a mean age of 60 years.5 The most common presenting 
symptom is vaginal bleeding as in our patient. The lesion often appears as a mass, plaque, or 
ulceration and frequently involves the distal one-third of the anterior vaginal wall.6 Huang 
reported that ulcerative and nodular tumors have a better five-year survival rate than cauliflower-
like lesions with 40%, 38%, and 20% survival respectively.7 Tumors less than three cm in size 
have a better prognosis with a median survival of 41 months compared to 12 months in tumors 
greater than three cm.8 Unlike cutaneous melanoma, the thickness of the lesion is not linked to 
prognosis. Positive lymph nodes are associated with lower median overall survival (7.8 months 
compared to 30 months for node-negative disease).5 Similarly, the SEER (Surveillance, 
Epidemiology and End Results) database shows 1.98 times increased risk of death for vaginal 
melanoma patients with positive lymph nodes.9 Five-year survival rates for vaginal melanoma 
are between 5%-32.3%.7,10,11 Our patient is still alive at five years which is unusual for a patient 
with regional metastasis.  
Treatment plans should be individualized and are dependent upon the location, size, clinical 
stage, and tumor markers. Exactly which staging guide to use is unclear for vaginal melanoma as 
no staging method adequately predicts prognosis. Some clinicians use the FIGO (International 
Federation of Gynecology and Obstetrics) staging and others use the AJCC (American Joint 
Commission on Cancer). In their review article, Gaducci et al stated that the AJCC system is 
recommended for vulvar and vaginal melanomas and the FIGO system for cervical melanomas.4 
Wide local excision offers patients the best chance of long-term survival.5 Adjuvant radiation can 
be used as in our patient for local disease control, but the evidence is lacking for its efficacy at 
increasing survival.9 A study out of MD Anderson reported less local recurrence and increased 
median overall survival with adjuvant radiotherapy after wide local excision (from 16.1 months 
to 29.4 months) but it was not statistically significant.5 Carbon ion beams could be useful in 
vulvovaginal melanomas with lymph node metastasis in the pelvis and groin with three-year 
local control rates of 49.9% and overall survival of 53.0%.12  
Limited data exist on the use of adjuvant systemic therapy in patients with mucosal melanoma 
because of difficulty enrolling patients in clinical trials. In one study, postoperative 
chemotherapy with temozolomide plus cisplatin, similar to the regimen our patient received, 
significantly prolonged median relapse-free survival when compared to interferon-alpha-2b 
alone or surgery alone, but there were only 21 patients with vulvar and 19 with vaginal disease 
included in this study.13 Temozolomide plus cisplatin had the best outcome for overall survival 
of 48.7 months versus 40.4 months with high dose interferon. Immunotherapy with IL-2, 
interferon-alpha, BCG, dendritic cells or lymphokine-activated killer cells may be beneficial as 
adjuvant therapy to surgery however this recommendation was from a retrospective study of 
mainly early-stage disease.7  
BRAF (encodes for protein B-Raf serine/threonine kinase), KIT (encodes for receptor tyrosine 
kinase protein) and NRAS (encodes a protein N-Ras that acts as a switch for receptor tyrosine 
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kinase) are oncogenes with the potential to cause normal cells to become cancerous and 
treatment may target them. BRAF is a common mutation found in about half of cutaneous 
melanomas,14 however only 10 percent of mucosal melanomas have mutations of BRAF, and 
approximately 25 percent have amplifications or somatic mutations of KIT.15,16,17 NRAS 
mutations may be found more often in vaginal as opposed to vulvar melanomas suggesting that 
these two anatomic locations may be immunologically different.4 Hou et al studied 51 cases of 
vulvar and vaginal melanoma samples obtained from multiple institutions and found 22% were 
positive for c-KIT compared to 3.5% of cutaneous and other nongynecological mucosal 
melanomas.18 They also found a difference in vulvar and vaginal melanomas with more KIT 
mutations in the vulvar (26.5%) compared to vaginal (8.3%) location. Hou et al found BRAF 
mutations in 26% of vulvovaginal melanomas. This is higher than seen in other series such as 
Aulmann et al who reported no BRAF mutations in 39 vulvar and 15 vaginal melanomas.19 Hou 
et al explains this difference by stating that her samples were oftentimes from metastatic lesions 
which may differ in frequency of mutation from primary lesions.18 Half of the BRAF mutations 
in Hou’s group were of the V600E type indicating a response to the drug vemurafenib, a 
selective inhibitor of the V600E mutant BRAF kinase. NRAS mutations were rare in this group 
of vulvovaginal melanomas (4%). PD-1 (programmed cell death) and PD-L1 (programmed cell 
death ligand) were seen in 75% and 56% of vulvovaginal melanomas in this series. 
  
In patients with metastatic cutaneous melanoma and a BRAF V600E/K mutation, the 
combination of a BRAF inhibitor (ex. vemurafenib, dabrafenib) and a MEK inhibitor (ex. 
cobimetinib, trametinib) has a longer progression-free survival, higher objective response rate, 
and longer overall survival compared with a BRAF inhibitor alone.20-22 For metastatic cutaneous, 
mucosal, and acral melanoma patients with a KIT mutation, the use of imatinib, a c-KIT 
inhibitor, in a phase II trial demonstrated better disease control however phase III data is not 
available.23 Two other studies suggest imatinib may be helpful in metastatic mucosal melanoma 
with KIT mutations, but the number of mucosal melanoma patients in the studies was small 
limiting the strength of the recommendation.15,24 In eleven vulvovaginal melanoma patients who 
were not surgical candidates, different combinations of biochemotherapy achieved a partial 
response with a median survival of ten months.25 The combination of anti-PD-1 (ex. 
pembrolizumab, nivolumab) and anti-CTLA4 (cytotoxic T lymphocyte-associated protein) (ex. 
ipilimumab) agents was more beneficial than single-agent anti-PD-1therapy in a pooled analysis 
of metastatic mucosal melanoma patients, however, median progression-free survival only 
improved by 2.9 months with 40% having grade 3 or 4 toxicity.26 
 
There are no consensus guidelines for the treatment of mucosal melanoma but an expert panel 
believes that it should be treated the same as cutaneous melanoma due to a lack of clinical trial 
data specific to mucosal disease.27 Cutaneous melanoma treatment has changed significantly 
since the introduction of immune checkpoint inhibitors and targeted therapy based on genetic 
mutations with exciting improvements in outcomes. Future treatments for mucosal melanomas 
may diverge from cutaneous disease because we have evidence that the disease sites differ in the 











We report a case of vaginal melanoma presenting with postmenopausal bleeding to raise 
awareness for this rare disease. Despite aggressive therapy, prognosis remains poor for most 
patients with vaginal melanoma. The key to improved survival is early detection and wide local 
excision of the lesion. We report this rare disease so physicians will consider it in their 
differential diagnosis for vaginal bleeding and perform repeat examinations when the usual 
evaluation and treatment for bleeding is not successful. Advances in immunotherapy and 
targeted therapy for vaginal melanoma may offer specific treatment options, however, until more 
evidence is available, the current recommendation is to treat with similar regimens used in 
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